<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145130</url>
  </required_header>
  <id_info>
    <org_study_id>EuroSkinGraft / ESG-01-2011</org_study_id>
    <nct_id>NCT02145130</nct_id>
  </id_info>
  <brief_title>Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects</brief_title>
  <official_title>A Phase I, Two Armed, Open, Prospective and Multicentre Study to Evaluate the Safety of Autologous Tissue-engineered Dermal Substitutes and Dermo-epidermal Skin Substitutes for the Treatment of Large Deep Partial and Full Thickness Skin Defects in Children and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluation of the safety of autologous tissue-engineered&#xD;
      dermal substitutes &quot;denovoDerm&quot; (first arm) and dermo-epidermal skin substitutes &quot;denovoSkin&quot;&#xD;
      (second arm) transplanted onto the wound bed in children and adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">March 2021</completion_date>
  <primary_completion_date type="Actual">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>denovoDerm: 4-6 days and 21 days after transplantation, denovoSkin 9-11 days and 21 days after transplantation</time_frame>
    <description>Assessment/reporting of local infection rate and graft take</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>until 90 days post transplantation</time_frame>
    <description>Assessment/reporting of number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Burn Injury</condition>
  <condition>Soft Tissue Injury</condition>
  <condition>Skin Necrosis</condition>
  <condition>Scars</condition>
  <condition>Congenital Giant Nevus</condition>
  <condition>Skin Tumors</condition>
  <arm_group>
    <arm_group_label>denovoDerm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous tissue-engineered dermal substitute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>denovoSkin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous tissue-engineered dermo-epidermal skin substitute</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denovoDerm</intervention_name>
    <description>Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin</description>
    <arm_group_label>denovoDerm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>denovoSkin</intervention_name>
    <description>Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed</description>
    <arm_group_label>denovoSkin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Deep partial or full thickness skin defect of at least 9 cm2 requiring surgical wound&#xD;
             coverage due to:&#xD;
&#xD;
               1. Acute cases: burn injury, soft tissue injury, skin necrosis after purpura&#xD;
                  fulminans&#xD;
&#xD;
               2. Reconstructive cases (elective surgery): scar formation after burn injuries,&#xD;
                  congenital giant nevus, skin tumours&#xD;
&#xD;
          -  Informed consent by patients/parents or other legal representatives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infected wounds or positive general microbiological swabs taken from the nose for&#xD;
             multi-resistant germs&#xD;
&#xD;
          -  Patients tested positive for HBV, HCV, syphilis or HIV&#xD;
&#xD;
          -  Patients with known underlying or concomitant medical conditions that may interfere&#xD;
             with normal wound healing (e.g. immune deficiency, systemic skin diseases, any kind of&#xD;
             congenital defect of metabolism including diabetes)&#xD;
&#xD;
          -  Coagulation disorders as defined by INR outside its normal value, PTT &gt;ULN and&#xD;
             fibrinogen &lt;LLN and / or at the Investigator's discretion&#xD;
&#xD;
          -  Previous enrolment of the patient into the current study&#xD;
&#xD;
          -  Participation of the patient in another study within 30 days preceding and during the&#xD;
             present study&#xD;
&#xD;
          -  Patients or parents/other legal representatives expected not to comply with the study&#xD;
             protocol&#xD;
&#xD;
          -  Suspicion of child abuse&#xD;
&#xD;
          -  Pregnant or breast feeding females&#xD;
&#xD;
          -  Contamination derived from biopsy which could interfere with patients health&#xD;
&#xD;
          -  Due to patient derived variations, isolated cells from biopsy do not proliferate or&#xD;
             proliferate insufficiently&#xD;
&#xD;
          -  Skin substitute has not been released due to production specific deviations&#xD;
&#xD;
          -  Patients allergic to amphotericin B and gentamicin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Böttcher, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital, Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Children's Hospital Zurich: denovoDerm</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Zurich: denovoSkin</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin</keyword>
  <keyword>Tissue-engineering</keyword>
  <keyword>Autologous</keyword>
  <keyword>Dermis</keyword>
  <keyword>Epidermis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Soft Tissue Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

